Using recombinant human G-CSF to treat chemotherapy-induced neutropenia over 3 decades: What is next?

<p>Chemotherapy-Induced Neutropenia (CIN) is a potentially fatal side effect of cancer treatment, affecting > 50% of cancer patients treated with chemotherapy. Clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has allowed for primary and secondary prophylaxis...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Jason Xu (Autore), Jonathan Sussman (Autore), Jessica Xu (Autore), Xing Zhao (Autore), Xiao Qiang Yan (Autore)
Natura: Libro
Pubblicazione: Annals of Bone Marrow Research - Peertechz Publications, 2023-09-12.
Soggetti:
Accesso online:Connect to this object online.
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_abmr_000010
042 |a dc 
100 1 0 |a Jason Xu  |e author 
700 1 0 |a  Jonathan Sussman  |e author 
700 1 0 |a  Jessica Xu  |e author 
700 1 0 |a  Xing Zhao  |e author 
700 1 0 |a Xiao Qiang Yan  |e author 
245 0 0 |a Using recombinant human G-CSF to treat chemotherapy-induced neutropenia over 3 decades: What is next? 
260 |b Annals of Bone Marrow Research - Peertechz Publications,   |c 2023-09-12. 
520 |a <p>Chemotherapy-Induced Neutropenia (CIN) is a potentially fatal side effect of cancer treatment, affecting > 50% of cancer patients treated with chemotherapy. Clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has allowed for primary and secondary prophylaxis of CIN and its sequela (i.e., febrile neutropenia, fatal infection) during myelosuppressive chemotherapy. Here, we review the translation and properties of first, second, and third-generation rhG-CSF molecules, including filgrastim (Neupogen, FDA approved in 1991) and biosimilars, pegfilgrastim (Neulasta, FDA approved in 2002) and biosimilars, and F-627 (Ryzneuta, NMPA approved in 2023), a novel long-acting rhG-CSF agent developed this past decade. Even with the development of increasingly personalized and targeted cancer therapy, chemotherapy, and stem cell transplantation remains a backbone for the majority of patients with advanced cancers, especially in the hematopoietic system. As such, more than 20 million cancer patients have been treated with rhG-CSF drugs since the first approval of filgrastim. In the next decade, we envision third-generation rhG-CSF products such as Ryzneuta lowering costs to patients and healthcare providers, expanding access to this essential medication for cancer patients worldwide, particularly for patients who require more aggressive chemotherapy treatment. </p> 
540 |a Copyright © Jason Xu et al. 
546 |a en 
655 7 |a Review Article  |2 local 
856 4 1 |u https://doi.org/10.17352/abmr.000010  |z Connect to this object online.